动态增强MRI纵向冲洗斜率变化预测乳腺癌对新辅助化疗的反应。

IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Yanbo Li, Jingbo Wang, Jinxia Guo, Caifeng Yue, Tianhui Liu, Yuchen Xue, Yuxin Cai, Wenqi Wang, Junnan Li, Jiahui Wang, Hong Lu
{"title":"动态增强MRI纵向冲洗斜率变化预测乳腺癌对新辅助化疗的反应。","authors":"Yanbo Li, Jingbo Wang, Jinxia Guo, Caifeng Yue, Tianhui Liu, Yuchen Xue, Yuxin Cai, Wenqi Wang, Junnan Li, Jiahui Wang, Hong Lu","doi":"10.1007/s00330-025-12042-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine whether wash-in slope (WIS) changes can predict pathologic complete response (pCR) following NAC in breast cancer.</p><p><strong>Materials and methods: </strong>This single-center retrospective study included consecutive females with breast cancer who received NAC followed by surgery between January 2016 and December 2022. All patients received dynamic contrast-enhanced MRI (DCE-MRI) pretreatment, after 2 cycles, 4 cycles, and after completion of treatment. The percentage change in tumor WIS from that before treatment (ΔWIS) was measured at each time point. Predictive performance for pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and across molecular subtypes.</p><p><strong>Results: </strong>A total of 162 patients were included in this study (mean age, 51.9 years ± 9.1 [SD]), and 43 (26.5%) achieved pCR. Overall, ΔWIS demonstrated comparable performance in predicting pCR after 2 cycles (AUC, 0.82; 95% CI: 0.73, 0.91), 4 cycles (AUC, 0.86; 95% CI: 0.78, 0.93), and after completion of NAC (AUC, 0.87; 95% CI: 0.8, 0.93), with no significant differences observed (all p > 0.05). Utilizing optimal threshold values of -33%, -44%, and -59% at each time point, ΔWIS yielded sensitivities ranging from 74.4% to 86.0% and specificities ranging from 75.6% to 80.7%. In molecular subtype analysis, ΔWIS after 4 cycles exhibited excellent predictive performance for pCR in triple-negative breast cancers (AUC, 0.96; 95% CI: 0.9, 1), outperforming its performance in Luminal B tumors (AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04).</p><p><strong>Conclusion: </strong>Tumor WIS changes from DCE-MRI could dynamically monitor neoadjuvant chemotherapy (NAC).</p><p><strong>Key points: </strong>Question Currently, there is no widely accepted standard imaging biomarker for predicting pCR in breast cancer patients undergoing NAC. Findings WIS changes outperformed tumor size in predicting pCR at four time points during NAC, and showed comparable predictive performance across all time points. Clinical relevance Longitudinal changes in the WIS derived from dynamic contrast-enhanced MRI enable real-time prediction of pathologic response to NAC in patients with breast cancer, supporting personalized treatment monitoring and decision-making.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer.\",\"authors\":\"Yanbo Li, Jingbo Wang, Jinxia Guo, Caifeng Yue, Tianhui Liu, Yuchen Xue, Yuxin Cai, Wenqi Wang, Junnan Li, Jiahui Wang, Hong Lu\",\"doi\":\"10.1007/s00330-025-12042-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine whether wash-in slope (WIS) changes can predict pathologic complete response (pCR) following NAC in breast cancer.</p><p><strong>Materials and methods: </strong>This single-center retrospective study included consecutive females with breast cancer who received NAC followed by surgery between January 2016 and December 2022. All patients received dynamic contrast-enhanced MRI (DCE-MRI) pretreatment, after 2 cycles, 4 cycles, and after completion of treatment. The percentage change in tumor WIS from that before treatment (ΔWIS) was measured at each time point. Predictive performance for pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and across molecular subtypes.</p><p><strong>Results: </strong>A total of 162 patients were included in this study (mean age, 51.9 years ± 9.1 [SD]), and 43 (26.5%) achieved pCR. Overall, ΔWIS demonstrated comparable performance in predicting pCR after 2 cycles (AUC, 0.82; 95% CI: 0.73, 0.91), 4 cycles (AUC, 0.86; 95% CI: 0.78, 0.93), and after completion of NAC (AUC, 0.87; 95% CI: 0.8, 0.93), with no significant differences observed (all p > 0.05). Utilizing optimal threshold values of -33%, -44%, and -59% at each time point, ΔWIS yielded sensitivities ranging from 74.4% to 86.0% and specificities ranging from 75.6% to 80.7%. In molecular subtype analysis, ΔWIS after 4 cycles exhibited excellent predictive performance for pCR in triple-negative breast cancers (AUC, 0.96; 95% CI: 0.9, 1), outperforming its performance in Luminal B tumors (AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04).</p><p><strong>Conclusion: </strong>Tumor WIS changes from DCE-MRI could dynamically monitor neoadjuvant chemotherapy (NAC).</p><p><strong>Key points: </strong>Question Currently, there is no widely accepted standard imaging biomarker for predicting pCR in breast cancer patients undergoing NAC. Findings WIS changes outperformed tumor size in predicting pCR at four time points during NAC, and showed comparable predictive performance across all time points. Clinical relevance Longitudinal changes in the WIS derived from dynamic contrast-enhanced MRI enable real-time prediction of pathologic response to NAC in patients with breast cancer, supporting personalized treatment monitoring and decision-making.</p>\",\"PeriodicalId\":12076,\"journal\":{\"name\":\"European Radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00330-025-12042-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00330-025-12042-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨冲洗斜率(WIS)变化是否能预测乳腺癌NAC术后的病理完全缓解(pCR)。材料和方法:这项单中心回顾性研究纳入了2016年1月至2022年12月期间接受NAC手术的连续女性乳腺癌患者。所有患者分别在2个周期、4个周期和治疗完成后接受动态对比增强MRI (DCE-MRI)预处理。在每个时间点测量肿瘤WIS较治疗前的百分比变化(ΔWIS)。通过对整个队列和跨分子亚型使用接受者工作特征曲线下面积(AUC)来评估pCR的预测性能。结果:本研究共纳入162例患者(平均年龄51.9岁±9.1 [SD]), 43例(26.5%)实现pCR。总体而言,ΔWIS在预测2个周期(AUC, 0.82; 95% CI: 0.73, 0.91)、4个周期(AUC, 0.86; 95% CI: 0.78, 0.93)和NAC完成后(AUC, 0.87; 95% CI: 0.8, 0.93)的pCR方面表现出相当的性能,没有观察到显著差异(均p < 0.05)。在每个时间点利用-33%,-44%和-59%的最佳阈值,ΔWIS产生的灵敏度范围为74.4%至86.0%,特异性范围为75.6%至80.7%。在分子亚型分析中,ΔWIS在4个周期后对三阴性乳腺癌的pCR预测表现优异(AUC, 0.96; 95% CI: 0.9, 1),优于其在Luminal B肿瘤中的表现(AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04)。结论:DCE-MRI对肿瘤WIS变化具有动态监测新辅助化疗(NAC)的作用。目前,还没有被广泛接受的标准成像生物标志物来预测乳腺癌NAC患者的pCR。研究发现,在NAC期间的四个时间点,WIS变化在预测pCR方面优于肿瘤大小,并且在所有时间点都显示出可比的预测性能。动态对比增强MRI得出的WIS纵向变化可以实时预测乳腺癌患者对NAC的病理反应,支持个性化治疗监测和决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer.

Objectives: To determine whether wash-in slope (WIS) changes can predict pathologic complete response (pCR) following NAC in breast cancer.

Materials and methods: This single-center retrospective study included consecutive females with breast cancer who received NAC followed by surgery between January 2016 and December 2022. All patients received dynamic contrast-enhanced MRI (DCE-MRI) pretreatment, after 2 cycles, 4 cycles, and after completion of treatment. The percentage change in tumor WIS from that before treatment (ΔWIS) was measured at each time point. Predictive performance for pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and across molecular subtypes.

Results: A total of 162 patients were included in this study (mean age, 51.9 years ± 9.1 [SD]), and 43 (26.5%) achieved pCR. Overall, ΔWIS demonstrated comparable performance in predicting pCR after 2 cycles (AUC, 0.82; 95% CI: 0.73, 0.91), 4 cycles (AUC, 0.86; 95% CI: 0.78, 0.93), and after completion of NAC (AUC, 0.87; 95% CI: 0.8, 0.93), with no significant differences observed (all p > 0.05). Utilizing optimal threshold values of -33%, -44%, and -59% at each time point, ΔWIS yielded sensitivities ranging from 74.4% to 86.0% and specificities ranging from 75.6% to 80.7%. In molecular subtype analysis, ΔWIS after 4 cycles exhibited excellent predictive performance for pCR in triple-negative breast cancers (AUC, 0.96; 95% CI: 0.9, 1), outperforming its performance in Luminal B tumors (AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04).

Conclusion: Tumor WIS changes from DCE-MRI could dynamically monitor neoadjuvant chemotherapy (NAC).

Key points: Question Currently, there is no widely accepted standard imaging biomarker for predicting pCR in breast cancer patients undergoing NAC. Findings WIS changes outperformed tumor size in predicting pCR at four time points during NAC, and showed comparable predictive performance across all time points. Clinical relevance Longitudinal changes in the WIS derived from dynamic contrast-enhanced MRI enable real-time prediction of pathologic response to NAC in patients with breast cancer, supporting personalized treatment monitoring and decision-making.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Radiology
European Radiology 医学-核医学
CiteScore
11.60
自引率
8.50%
发文量
874
审稿时长
2-4 weeks
期刊介绍: European Radiology (ER) continuously updates scientific knowledge in radiology by publication of strong original articles and state-of-the-art reviews written by leading radiologists. A well balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes ER an indispensable source for current information in this field. This is the Journal of the European Society of Radiology, and the official journal of a number of societies. From 2004-2008 supplements to European Radiology were published under its companion, European Radiology Supplements, ISSN 1613-3749.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信